Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without H...

por Koyama, Kumiko, Ishikawa, Hirokazu, Abe, Manabu, Shiose, Yoshinobu, Ueno, Suguru, Qiu, Yang, Nakamaru, Kenji, Murakami, Masato
Publicado 2022

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma

por Koul, Dimpy, Wang, Shuzhen, Wu, Shaofang, Saito, Norihiko, Zheng, Siyuan, Gao, Feng, Kaul, Isha, Setoguchi, Masaki, Nakayama, Kiyoshi, Koyama, Kumiko, Shiose, Yoshinobu, Sulman, Erik P., Hirota, Yasuhide, Yung, W.K. Alfred
Publicado 2017

Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423

por Kashiyama, Tomoko, Oda, Katsutoshi, Ikeda, Yuji, Shiose, Yoshinobu, Hirota, Yasuhide, Inaba, Kanako, Makii, Chinami, Kurikawa, Reiko, Miyasaka, Aki, Koso, Takahiro, Fukuda, Tomohiko, Tanikawa, Michihiro, Shoji, Keiko, Sone, Kenbun, Arimoto, Takahide, Wada-Hiraike, Osamu, Kawana, Kei, Nakagawa, Shunsuke, Matsuda, Koichi, McCormick, Frank, Aburatani, Hiroyuki, Yano, Tetsu, Osuga, Yutaka, Fujii, Tomoyuki
Publicado 2014